2023
The correlation of psoriasis and its treatment medications with lumbar discectomy postoperative infections
Day W, Ch'en P, Ratnasamy P, Jeong S, Varthi A, Grauer J. The correlation of psoriasis and its treatment medications with lumbar discectomy postoperative infections. The Spine Journal 2023, 23: 1623-1629. PMID: 37355045, DOI: 10.1016/j.spinee.2023.06.392.Peer-Reviewed Original ResearchSurgical site infectionRisk of SSIPostoperative surgical site infectionElixhauser Comorbidity IndexMultivariable logistic regressionTopical therapyComorbidity indexReoperation rateSite infectionTreatment medicationsMultivariable analysisDiscectomy patientsGreater oddsFive-Year Reoperation RatesSingle-level lumbar discectomyLogistic regressionCorrelation of psoriasisOral systemic treatmentInfection-related complicationsAdministrative database studyDay of surgeryLog-rank testNational administrative databaseRetrospective case controlUS adult populationAnalysis of Drugs in Saliva of US Military Veterans Treated for Substance Use Disorders Using Supported Liquid Extraction and Surface-Enhanced Raman Spectral Analysis
Farquharson S, Shende C, Newcomb J, Petrakis I, Arias A. Analysis of Drugs in Saliva of US Military Veterans Treated for Substance Use Disorders Using Supported Liquid Extraction and Surface-Enhanced Raman Spectral Analysis. Molecules 2023, 28: 2010. PMID: 36903255, PMCID: PMC10004423, DOI: 10.3390/molecules28052010.Peer-Reviewed Original ResearchConceptsOpioid use disorderSubstance-related disordersUS military veteransUse disordersMilitary veteransDrug useIllicit drugsSubstance use disordersDrug overdose deathsIllicit drug useML of salivaBuprenorphine adherenceTreatment medicationsUrine testsOverdose deathsPatients' salivaDisease controlPatient samplesBuprenorphinePOC analyzerDrugsVulnerable populationsCare analyzerMedicationsDisorders
2021
Emergency Department Treatment of Opioid Use Disorder
Samuels E, Coupet E, D’Onofrio G. Emergency Department Treatment of Opioid Use Disorder. 2021, 57-75. DOI: 10.1007/978-3-030-80818-1_5.ChaptersOpioid use disorderED visitsUse disordersUntreated opioid use disorderDrug-related emergency department visitsNonfatal opioid overdoseUS ED visitsEmergency department treatmentFirst-line treatmentLow-dose ketamineEmergency department visitsIllicit opioid useDosage of medicationRegional nerve blocksAddiction treatment medicationsHarm reduction servicesTake-home naloxoneCost-effective treatmentAcute painOpioid useDepartment visitsOUD treatmentTreatment medicationsNerve blockOpioid agonistsReadiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation
Edelman EJ, Gan G, Dziura J, Esserman D, Morford KL, Porter E, Chan PA, Cornman DH, Oldfield BJ, Yager JE, Muvvala SB, Fiellin DA. Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2021, 87: 959-970. PMID: 33675619, PMCID: PMC8192340, DOI: 10.1097/qai.0000000000002666.Peer-Reviewed Original ResearchConceptsHIV clinicTreatment medicationsMixed-methods formative evaluationAddiction treatmentTreatment-eligible patientsSubscale scoresAddiction treatment medicationsAdverse health consequencesHIV careMedication complexityTobacco useMedicationsClinicHealth consequencesSite specialistMultidisciplinary teamworkBehavioral servicesTreatment modelOpioidsLocal championsVariable experienceInconsistent availabilityAddiction treatment modelsFocus groupsTreatment
2019
Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O'Connor PG, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial. The Lancet HIV 2019, 6: e509-e517. PMID: 31109915, PMCID: PMC7161741, DOI: 10.1016/s2352-3018(19)30076-1.Peer-Reviewed Original ResearchConceptsAlcohol use disorderWeek 24Use disordersAlcohol treatmentAdverse eventsNumber of drinksTreatment medicationsPhysician managementAlcohol abuseMental Disorders-IV criteriaAlcohol-related careFormal alcohol treatmentKey exclusion criteriaTimeline followback methodMotivational enhancement therapyTreat populationHIV clinicHIV outcomesPrimary outcomeSpecialty referralsMean ageUS National InstitutesWeek 4Medical conditionsExclusion criteriaA randomized trial of decision support for tobacco dependence treatment in an inpatient electronic medical record: clinical results
Bernstein SL, Weiss J, DeWitt M, Tetrault JM, Hsiao AL, Dziura J, Sussman S, Miller T, Carpenter K, O’Connor P, Toll B. A randomized trial of decision support for tobacco dependence treatment in an inpatient electronic medical record: clinical results. Implementation Science 2019, 14: 8. PMID: 30670043, PMCID: PMC6343239, DOI: 10.1186/s13012-019-0856-8.Peer-Reviewed Original ResearchConceptsPatient's primary care providerPrimary care providersTobacco treatment medicationsElectronic health recordsTobacco use disorderQuit ratesTreatment medicationsProblem listCare providersUse disordersOne-year quit ratesState tobacco quitlineTobacco quit ratesPrescription of medicationsTobacco dependence treatmentProcess of careSingle hospital systemElectronic medical recordsInpatient electronic medical recordPatient's problem listSustained quittingAdult patientsControl patientsCurrent smokingHospitalized smokers
2017
Design and implementation of decision support for tobacco dependence treatment in an inpatient electronic medical record: a randomized trial
Bernstein SL, Rosner J, DeWitt M, Tetrault J, Hsiao AL, Dziura J, Sussman S, O'Connor P, Toll B. Design and implementation of decision support for tobacco dependence treatment in an inpatient electronic medical record: a randomized trial. Translational Behavioral Medicine 2017, 7: 185-195. PMID: 28194729, PMCID: PMC5526813, DOI: 10.1007/s13142-017-0470-8.Peer-Reviewed Original ResearchConceptsPatient's primary care providerTobacco dependence treatmentTobacco treatment medicationsElectronic health recordsPrimary care providersState Smokers' QuitlineTobacco use disorderDependence treatmentTreatment medicationsIntervention physiciansProblem listUse disordersOrder setsState tobacco quitlineCluster-randomized trialLong-term cessationElectronic medical recordsInpatient electronic medical recordPatient's problem listSmokers resultsAdult patientsHospital dischargeHospitalized smokersElectronic alertsTobacco treatment
2015
Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes
Steiner AZ, Diamond MP, Legro RS, Schlaff WD, Barnhart KT, Casson PR, Christman GM, Alvero R, Hansen KR, Geisler WM, Thomas T, Santoro N, Zhang H, Eisenberg E, Network R. Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes. Fertility And Sterility 2015, 104: 1522-1526. PMID: 26413816, PMCID: PMC4663111, DOI: 10.1016/j.fertnstert.2015.08.022.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, BacterialBiomarkersChi-Square DistributionChlamydia InfectionsChlamydia trachomatisEnzyme-Linked Immunosorbent AssayFallopian TubesFemaleHumansImmunoglobulin GInfertility, FemaleLinear ModelsLive BirthMultivariate AnalysisOdds RatioPredictive Value of TestsPregnancyPregnancy RatePregnancy, EctopicReproductive Techniques, AssistedRisk AssessmentRisk FactorsSerologic TestsTreatment OutcomeUltrasonographyYoung AdultConceptsEctopic pregnancySeropositive womenInfertile womenTubal patencyLive birthsPolycystic Ovary Syndrome IIChlamydia trachomatis seropositivityMultiple Intrauterine GestationsPatent fallopian tubesEnzyme-linked immunosorbentCurrent alcohol useC. trachomatis elementary bodiesOvarian stimulationCohort studyIntrauterine gestationPregnancy outcomesPrimary outcomeTreatment medicationsPatent tubesSmoking statusOutpatient clinicIgG3 antibodiesFallopian tubeRelative riskMAIN OUTCOME
2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLX
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply